@article{LeikamHufnagelOttoetal.2015,
  author    = {Leikam, C and Hufnagel, AL and Otto, C and Murphy, DJ and M{\"u}hling, B and Kneitz, S and Nanda, I and Schmid, M and Wagner, TU and Haferkamp, S and Br{\"o}cker, E-B and Schartl, M and Meierjohann, S},
  title     = {In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells},
  series = {Cell Death and Disease},
  volume    = {6},
  journal   = {Cell Death and Disease},
  number    = {e1711},
  doi       = {10.1038/cddis.2015.71},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148718},
  year      = {2015},
  abstract  = {Oncogenic signaling in melanocytes results in oncogene-induced senescence (OIS), a stable cell-cycle arrest frequently characterized by a bi-or multinuclear phenotype that is considered as a barrier to cancer progression. However, the long-sustained conviction that senescence is a truly irreversible process has recently been challenged. Still, it is not known whether cells driven into OIS can progress to cancer and thereby pose a potential threat. Here, we show that prolonged expression of the melanoma oncogene N-RAS\(^{61K}\) in pigment cells overcomes OIS by triggering the emergence of tumor-initiating mononucleated stem-like cells from senescent cells. This progeny is dedifferentiated, highly proliferative, anoikis-resistant and induces fast growing, metastatic tumors. Our data describe that differentiated cells, which are driven into senescence by an oncogene, use this senescence state as trigger for tumor transformation, giving rise to highly aggressive tumor-initiating cells. These observations provide the first experimental in vitro evidence for the evasion of OIS on the cellular level and ensuing transformation.},
  language  = {en}
}
@article{SchattonYangKleffeletal.2015,
  author    = {Schatton, Tobias and Yang, Jun and Kleffel, Sonja and Uehara, Mayuko and Barthel, Steven R. and Schlapbach, Christoph and Zhan, Qian and Dudeney, Stephen and Mueller, Hansgeorg and Lee, Nayoung and de Vries, Juliane C. and Meier, Barbara and Beken, Seppe Vander and Kluth, Mark A. and Ganss, Christoph and Sharpe, Arlene H. and Waaga-Gasser, Ana Maria and Sayegh, Mohamed H. and Abdi, Reza and Scharffetter-Kochanek, Karin and Murphy, George F. and Kupper, Thomas S. and Frank, Natasha Y. and Frank, Markus H.},
  title     = {ABCB5 Identifies Immunoregulatory Dermal Cells},
  series = {Cell Reports},
  volume    = {12},
  journal   = {Cell Reports},
  doi       = {10.1016/j.celrep.2015.08.010},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-149989},
  pages     = {1564 -- 1574},
  year      = {2015},
  abstract  = {Cell-based strategies represent a new frontier in the treatment of immune-mediated disorders. However, the paucity of markers for isolation of molecularly defined immunomodulatory cell populations poses a barrier to this field. Here, we show that ATP-binding cassette member B5 (ABCB5) identifies dermal immunoregulatory cells (DIRCs) capable of exerting therapeutic immunoregulatory functions through engagement of programmed cell death 1 (PD-1). Purified Abcb5\(^+\) DIRCs suppressed T cell proliferation, evaded immune rejection, homed to recipient immune tissues, and induced Tregs in vivo. In fully major-histocompatibility-complex-mismatched cardiac allotransplantation models, allogeneic DIRCs significantly prolonged allograft survival. Blockade of DIRC-expressed PD-1 reversed the inhibitory effects of DIRCs on T cell activation, inhibited DIRC-dependent Treg induction, and attenuated DIRC-induced prolongation of cardiac allograft survival, indicating that DIRC immunoregulatory function is mediated, at least in part, through PD-1. Our results identify ABCB5\(^+\) DIRCs as a distinct immunoregulatory cell population and suggest promising roles of this expandable cell subset in cellular immunotherapy.},
  language  = {en}
}